Bristol Myers' breast cancer drug cuts progression risk by 59% in late-stage trial
Per Reuters, Bristol Myers Squibb and SystImmune say their breast cancer drug cut the risk of progression or death by 59% in a phase 3 trial.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Bristol Myers Squibb and partner SystImmune reported on Friday that their experimental breast cancer therapy delayed disease progression better than standard chemotherapy in a late-stage trial, according to Reuters.
The drug, izalontamab brengitecan, lowered the chance of worsening or death by 59% among patients with advanced HR-positive, HER2-negative breast cancer who had already undergone at least one earlier chemotherapy regimen. Those on the drug went an average of 8.2 months without tumor growth, versus four months with standard chemo.
Detailed findings will be shown at the ESMO meeting in Madrid.
why it matters
For Bristol Myers, the data add a clinical milestone in oncology, where patients with limited options form a key market. Investors typically weigh such readouts alongside safety data and the complete presentation, so the stock reaction will depend on details not yet shared in this update.
market impact
Bristol Myers Squibb: positive phase 3 data may support sentiment around the company's oncology pipeline
tags
instruments
sources
- Bristol Myers, SystImmune drug cuts breast cancer progression risk in study — Reuters, 23 October 2026 at 11:53 UTC
- Bristol Myers Says Breast Cancer Drug IZA-BREN Reduces Risk Of Progression Or Death By 59% In Phase 3 Study — Reuters, 23 October 2026 at 12:16 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗